https://pharminent.com/regulatory-round-up-novartis-sanofi-and-arrowhead-secure-chmp-blessings/ 2026-04-24T16:08:43Z Pharminent en Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings 2026-04-24T13:45:58Z Blog https://pharminent.com/daiichi-sankyo-shares-slip-after-delaying-annual-earnings-report/ 2026-04-24T16:08:46Z Pharminent en Daiichi Sankyo shares slip after delaying annual earnings report 2026-04-24T12:44:59Z Blog https://pharminent.com/pfizer-culls-early-pd-l1-asset-after-series-of-clinical-wins-deals-in-cancer/ 2026-04-24T16:08:48Z Pharminent en Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer 2026-04-24T12:44:24Z Blog https://pharminent.com/avalyn-seeks-public-debut-to-support-new-lung-drug-formulations/ 2026-04-24T16:08:50Z Pharminent en Avalyn seeks public debut to support new lung drug formulations 2026-04-24T12:02:00Z Blog https://pharminent.com/beyond-formulary-access-building-a-scalable-pharmaceutical-manufacturer-commercial-platform-for-direct-to-consumer-and-employer-channels/ 2026-04-24T16:08:52Z Pharminent en Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels 2026-04-24T11:00:00Z Blog https://pharminent.com/ozmosi-and-planview-partner-to-enhance-pharmaceutical-data-integration/ 2026-04-24T16:08:52Z Pharminent en OZMOSI and Planview partner to enhance pharmaceutical data integration 2026-04-24T10:54:29Z Blog https://pharminent.com/cardiometabolic-trials-using-expertise-to-turn-complexity-into-robust-results/ 2026-04-24T16:08:54Z Pharminent en Cardiometabolic trials: Using expertise to turn complexity into robust results 2026-04-24T10:36:17Z Blog https://pharminent.com/regeneron-cuts-white-house-pricing-deal-offers-new-gene-therapy-for-free/ 2026-04-24T16:08:55Z Pharminent en Regeneron cuts White House pricing deal, offers new gene therapy for free 2026-04-24T10:12:25Z Blog https://pharminent.com/cumberland-to-sell-drug-portfolio-to-apotex-for-100m/ 2026-04-24T16:08:56Z Pharminent en Cumberland to sell drug portfolio to Apotex for $100m 2026-04-24T09:33:03Z Blog https://pharminent.com/fda-clears-first-genetic-hearing-loss-gene-therapy/ 2026-04-24T16:08:56Z Pharminent en FDA clears first genetic hearing loss gene therapy 2026-04-24T09:22:53Z Blog https://pharminent.com/cumberland-to-sell-drug-portfolio-to-apotex-for-100m-2/ 2026-04-24T16:08:57Z Pharminent en Cumberland to sell drug portfolio to Apotex for $100m 2026-04-24T09:14:46Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-april-23-2026/ 2026-04-23T21:14:13Z Pharminent en Rare Disease & Gene Therapy Digest • April 23, 2026 2026-04-23T21:14:10Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-23-2026/ 2026-04-23T21:02:27Z Pharminent en Strategic News Watch • April 23, 2026 2026-04-23T21:02:24Z Blog https://pharminent.com/fda-approves-regenerons-hearing-loss-gene-therapy/ 2026-04-24T16:08:57Z Pharminent en FDA approves Regeneron's hearing loss gene therapy 2026-04-23T19:33:00Z Blog https://pharminent.com/fda-approves-first-ever-gene-therapy-for-treatment-of-genetic-hearing-loss-under-national-priority-voucher-program/ 2026-04-24T16:08:58Z Pharminent en FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program 2026-04-23T19:25:59Z Blog https://pharminent.com/cms-extends-medicares-short-term-bridge-program-for-glp-1-obesity-drug-coverage/ 2026-04-24T16:02:28Z Pharminent en CMS Extends Medicare's Short-Term Bridge Program for GLP-1 Obesity Drug Coverage 2026-04-23T18:42:29Z Blog https://pharminent.com/drugmaker-abbvie-chooses-north-carolina-for-1-4b-manufacturing-campus/ 2026-04-24T16:02:32Z Pharminent en Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus 2026-04-23T16:56:00Z Blog https://pharminent.com/roche-facing-biosimilar-threats-puts-faith-in-new-cancer-and-obesity-drugs/ 2026-04-24T16:02:33Z Pharminent en Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs 2026-04-23T16:04:00Z Blog https://pharminent.com/sanofi-posts-upbeat-sales-as-rd-pressure-builds/ 2026-04-23T20:37:15Z Pharminent en Sanofi posts upbeat sales as R&D pressure builds 2026-04-23T15:02:00Z Blog https://pharminent.com/bbot-shakes-up-leadership-as-ras-competitors-get-more-visibility/ 2026-04-23T20:37:17Z Pharminent en BBOT shakes up leadership as RAS competitors get more visibility 2026-04-23T14:58:54Z Blog https://pharminent.com/novo-says-oral-semaglutide-works-in-diabetic-kids/ 2026-04-23T20:37:19Z Pharminent en Novo says oral semaglutide works in diabetic kids 2026-04-23T14:29:35Z Blog https://pharminent.com/sanofi-defends-dupixent-patents-but-execs-insist-it-has-nothing-to-do-with-ceo-change/ 2026-04-23T20:37:21Z Pharminent en Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change 2026-04-23T13:49:04Z Blog https://pharminent.com/cms-and-fda-announce-rapid-coverage-pathway-to-accelerate-patient-access-to-life-changing-medical-devices/ 2026-04-23T20:37:22Z Pharminent en CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices 2026-04-23T12:50:46Z Blog https://pharminent.com/unnamed-pharma-files-citizen-petition-targeting-fdas-trove-of-rejection-letters/ 2026-04-23T20:37:24Z Pharminent en Unnamed pharma files citizen petition targeting FDA's trove of rejection letters 2026-04-23T11:56:31Z Blog https://pharminent.com/roche-insists-amylin-obesity-drug-still-valuable-for-patients-who-dont-want-side-effects/ 2026-04-23T20:37:25Z Pharminent en Roche insists amylin obesity drug still valuable for patients who 'don't want side effects' 2026-04-23T11:55:46Z Blog https://pharminent.com/aan-2026-jj-kyverna-capricor-and-praxis-showcase-practice-changing-data/ 2026-04-23T20:37:26Z Pharminent en AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data 2026-04-23T11:34:39Z Blog https://pharminent.com/minnesotas-340b-hospitals-make-one-billion-more-from-340b-than-they-spend-on-uncompensated-care/ 2026-04-23T20:37:28Z Pharminent en Minnesota's 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care 2026-04-23T11:00:00Z Blog https://pharminent.com/sanofi-receives-fda-approval-for-tzield-in-paediatric-diabetes/ 2026-04-23T20:37:29Z Pharminent en Sanofi receives FDA approval for Tzield in paediatric diabetes 2026-04-23T10:05:43Z Blog https://pharminent.com/abbvie-opts-for-north-carolina-to-house-1-4bn-manufacturing-site/ 2026-04-23T20:37:29Z Pharminent en AbbVie opts for North Carolina to house $1.4bn manufacturing site 2026-04-23T09:36:58Z Blog https://pharminent.com/msd-teams-up-with-google-cloud-on-agentic-ai-transformation/ 2026-04-23T20:37:30Z Pharminent en MSD teams up with Google Cloud on agentic AI transformation 2026-04-23T09:30:13Z Blog https://pharminent.com/abbvie-makes-record-investment-in-north-carolina-plant/ 2026-04-23T20:37:30Z Pharminent en AbbVie makes record investment in North Carolina plant 2026-04-23T08:37:34Z Blog https://pharminent.com/fda-releases-congressional-justification-for-fy-2027-budget-including-proposal-regarding-interchangeability-of-biosimilars/ 2026-04-23T16:44:15Z Pharminent en FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars 2026-04-22T21:21:33Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-22-2026/ 2026-04-22T17:48:50Z Pharminent en Strategic News Watch • April 22, 2026 2026-04-22T17:48:47Z Blog https://pharminent.com/medicare-weight-loss-drug-pilot-on-ice-as-insurers-decline-to-contribute/ 2026-04-23T16:44:18Z Pharminent en Medicare weight loss drug pilot on ice as insurers decline to contribute 2026-04-22T16:28:04Z Blog https://pharminent.com/revolution-drug-shows-promise-in-early-pancreatic-cancer/ 2026-04-23T16:44:20Z Pharminent en Revolution drug shows promise in early pancreatic cancer 2026-04-22T15:50:00Z Blog https://pharminent.com/moderna-after-losing-us-funding-rebounds-to-start-mrna-bird-flu-vaccine-trial/ 2026-04-22T16:19:02Z Pharminent en Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial 2026-04-22T15:21:00Z Blog https://pharminent.com/trumps-psychedelics-push-a-mixed-blessing-for-neuropsychiatric-companies-patients/ 2026-04-22T16:19:05Z Pharminent en Trump's psychedelics push a mixed blessing for neuropsychiatric companies, patients 2026-04-22T14:59:05Z Blog https://pharminent.com/neurology-biomanufacturing-start-ups-bag-uk-ai-funding/ 2026-04-22T16:19:08Z Pharminent en Neurology, biomanufacturing start-ups bag UK AI funding 2026-04-22T13:21:48Z Blog https://pharminent.com/ionis-antisense-drug-stabilizes-ultra-rare-disease-ahead-of-fda-decision/ 2026-04-22T16:19:09Z Pharminent en Ionis' antisense drug stabilizes ultra-rare disease ahead of FDA decision 2026-04-22T13:18:29Z Blog https://pharminent.com/lilly-exits-rigel-alliance-adding-to-ripk1-scrap-heap/ 2026-04-22T16:19:11Z Pharminent en Lilly exits Rigel alliance, adding to RIPK1 scrap heap 2026-04-22T12:55:40Z Blog https://pharminent.com/fda-delays-decision-on-sanofis-subcutaneous-sarclisa/ 2026-04-22T16:19:13Z Pharminent en FDA delays decision on Sanofi's subcutaneous Sarclisa 2026-04-22T12:25:24Z Blog https://pharminent.com/msd-backed-ray-locks-in-125m-to-back-eye-drug-pipeline/ 2026-04-22T16:19:15Z Pharminent en MSD-backed Ray locks in $125m to back eye drug pipeline 2026-04-22T11:57:43Z Blog https://pharminent.com/new-data-build-case-for-roches-oral-btk-drug-for-ms/ 2026-04-22T16:19:16Z Pharminent en New data build case for Roche's oral BTK drug for MS 2026-04-22T11:36:30Z Blog https://pharminent.com/pivotal-trial-of-modernas-h5n1-bird-flu-jab-gets-underway/ 2026-04-22T16:19:17Z Pharminent en Pivotal trial of Moderna's H5N1 bird flu jab gets underway 2026-04-22T10:30:55Z Blog https://pharminent.com/bioaegis-and-prenosis-partner-for-inflammatory-disease-therapies/ 2026-04-22T16:19:18Z Pharminent en BioAegis and Prenosis partner for inflammatory disease therapies 2026-04-22T09:57:07Z Blog https://pharminent.com/bioaegis-and-prenosis-partner-for-inflammatory-disease-therapies-2/ 2026-04-22T16:19:18Z Pharminent en BioAegis and Prenosis partner for inflammatory disease therapies 2026-04-22T09:31:46Z Blog https://pharminent.com/medicare-obesity-drug-pilot-extended-after-insurer-pushback/ 2026-04-22T16:19:19Z Pharminent en Medicare obesity drug pilot extended after insurer pushback 2026-04-22T09:27:37Z Blog https://pharminent.com/health-canada-approves-biocons-two-denosumab-biosimilars-2/ 2026-04-22T16:19:20Z Pharminent en Health Canada approves Biocon's two denosumab biosimilars 2026-04-22T07:35:53Z Blog